Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Results reinforce commitment to next-generation oral SERD development programme
Subscribe To Our Newsletter & Stay Updated
